Hematology-Oncologyaxi-celCD19-CAR-T therapy
Structural Differences in Tisa-cel and Axi-cel CAR-T Therapies and Their Impact on CD19 Resistance in B-cell Malignancies
By MedXY|Sep 1, 2026
Distinct CAR architectures in tisa-cel (4-1BB costimulation) and axi-cel (CD28 costimulation) influence mechanisms of resistance through CD19 loss, affecting relapse rates in B-cell malignancies treated with CD19-CAR-T therapies.
